CXCR4 and renal fibrosis: Since the i-body alone has a short half-life in blood and lower affinity, we sought to test if the second-generation Fc-fused anti-CXCR4 i-body AD-214 could mitigate renal fibrosis when given at a lower dosage and a longer dosing interval than AD-114.